by Juan Carlos Serna, SVP, Scientific and Clinical Affairs, AngioDynamics
Running a clinical trial for novel therapeutic discovery is expensive — they run from $12.2 million — $33.1 million per trial.[1] When a trial fails to complete, there are significant financial repercussions, resource wasting, and, more importantly, potential human cost. Terminated or inefficient clinical trials substantially slow our ability to get life-changing treatments into the hands of the people who need them. Artificial Intelligence (AI) is an untapped resource that can help us more accurately predict whether or not a clinical trial will be successful.
AngioDynamics
A leading provider of innovative, minimally invasive medical devices used by healthcare providers for vascular access, peripheral vascular disease and oncology.
